Merck's KEYTRUDA and WELIREG Show Promising Results in Kidney Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 28 2026
0mins
Should l Buy MRK?
Source: Businesswire
- Clinical Trial Results: At the 2026 American Society of Clinical Oncology (ASCO) meeting, Merck presented results from the LITESPARK-022 Phase 3 trial, demonstrating that the combination of KEYTRUDA and WELIREG significantly improved disease-free survival in renal cell carcinoma patients, reducing the risk of recurrence or death by 28% (HR=0.72, p=0.0003), offering new hope for kidney cancer treatment.
- Significant Patient Benefit: In the first pre-specified interim analysis with a median follow-up of 28.4 months, the 24-month disease-free survival rate was 80.7% for the KEYTRUDA plus WELIREG arm, notably higher than the 73.7% for KEYTRUDA monotherapy, providing a new treatment option for high-risk patients that could reshape clinical practice.
- FDA Priority Review: Following the positive results from LITESPARK-022, the FDA has accepted priority review applications for the combination of WELIREG with KEYTRUDA, with a target action date set for June 19, 2026, which could provide more effective treatment options for kidney cancer patients if approved.
- Good Safety Profile: The safety profile of the KEYTRUDA and WELIREG combination was consistent with previously reported studies, with no new safety signals observed, and 69.5% of patients completing the treatment, indicating good tolerability and enhancing its potential for clinical application.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 115.680
Low
95.00
Averages
119.53
High
139.00
Current: 115.680
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MERCK CLOSES IN ON $6BN BIOTECH ACQUISITION TO ENHANCE CANCER DRUG PORTFOLIO - FT
- Merck's Acquisition: Merck is set to acquire a biotechnology company for approximately $6 billion to enhance its cancer drug pipeline.
- Strategic Focus: This deal reflects Merck's commitment to expanding its portfolio in oncology and strengthening its position in the competitive cancer treatment market.
See More
SLS vs. TERN: Which Pharmaceutical Stock Offers Greater Potential as Merck Plans $6B Investment in Cancer Ahead of Keytruda Patent Expiration?
Leukemia Therapies Advancements: SLS and TERN are making progress in leukemia therapies, with TERN-701 targeting chronic myeloid leukemia (CML) and SLS focusing on a maintenance immunotherapy for acute myeloid leukemia (AML), both expected to have Phase 3 readouts by 2026.
Market Sentiment Shift: Retail sentiment has shifted, with TERN moving to a bullish outlook while SLS has adopted a bearish stance, reflecting differing investor confidence in their respective stocks.
Financial Opportunities and Strategies: Merck anticipates a $70 billion commercial opportunity beyond Keytruda, as it prepares for the expected loss of exclusivity in 2028, while also expanding its newer Keytruda QLEX formulation.
Stock Performance and Analyst Ratings: SLS stocks have shown a significant upside potential, with a consensus rating of 'Strong Buy', while TERN's stock has also gained traction, reflecting a broader positive sentiment in the oncology sector.
See More
Merck Nears $6 Billion Acquisition of Terns Pharmaceuticals
- Acquisition Progress: Merck & Co. is nearing an approximately $6 billion all-cash deal to acquire US biotech firm Terns Pharmaceuticals, aiming to bolster its drug pipeline ahead of the patent expiration of cancer treatment Keytruda.
- Positive Market Reaction: Following the news, Terns Pharmaceuticals' shares rose about 10% in after-hours trading, reflecting optimistic market sentiment and indicating investor confidence in its chronic myeloid leukemia treatment potential.
- Strategic Positioning: Merck CEO Rob Davis is spearheading a diversification strategy to enhance the company's competitiveness ahead of Keytruda's patent expiration in 2028, demonstrating a strong commitment to future drug development.
- Market Capitalization: As of Tuesday's close, Terns had a market capitalization of $5.4 billion, and Merck's acquisition intentions not only aim to enhance its drug portfolio but also potentially lay the groundwork for future growth.
See More
MERCK AND TERNS IN FINAL STAGES OF DISCUSSIONS, DEAL POSSIBLE SOON - FT
- Negotiations Update: Talks between Merck and Terna are currently taking place at an advanced stage.
- Potential Agreement: A deal between the two companies could be reached in the coming days.
See More
MERCK'S CASH OFFER IS PROJECTED TO VALUATE TERNS AT ABOUT $6 BILLION - FT
- Merck's All-Cash Deal: Merck is expected to finalize an all-cash deal valued at approximately $6 billion.
- Valuation Expectations: The deal is anticipated to significantly enhance Merck's market valuation.
See More
Organon 2025 Financial Results and Outlook Analysis
- Revenue Decline: Organon reported approximately $6.216 billion in revenue for 2025, a 3% year-over-year decline, reflecting challenges in its women's health and biosimilars segments, particularly a 9% drop in the U.S. market due to policy-related access restrictions.
- Leadership Change: CEO Kevin Ali resigned following an internal investigation, with Joseph Morrissey appointed as interim CEO; while the financial impact of this change is described as small, it has affected investor sentiment and led to stock price volatility.
- Cash Flow and Debt Management: In 2025, Organon generated about $700 million in net cash flow, and despite facing total debt of $8.64 billion, management is focused on debt reduction, aiming to significantly lower net debt levels before the 2028 refinancing deadline.
- Portfolio Risk: Although the biosimilars segment grew by 4% in 2025, the decline in sales of mature products like Nexplanon by 4% and market access restrictions indicate that Organon's product portfolio faces ongoing market pressures, limiting future growth potential.
See More
MERCK CLOSES IN ON $6BN BIOTECH ACQUISITION TO ENHANCE CANCER DRUG PORTFOLIO - FT
- Merck's Acquisition: Merck is set to acquire a biotechnology company for approximately $6 billion to enhance its cancer drug pipeline.
- Strategic Focus: This deal reflects Merck's commitment to expanding its portfolio in oncology and strengthening its position in the competitive cancer treatment market.
See More
SLS vs. TERN: Which Pharmaceutical Stock Offers Greater Potential as Merck Plans $6B Investment in Cancer Ahead of Keytruda Patent Expiration?
Leukemia Therapies Advancements: SLS and TERN are making progress in leukemia therapies, with TERN-701 targeting chronic myeloid leukemia (CML) and SLS focusing on a maintenance immunotherapy for acute myeloid leukemia (AML), both expected to have Phase 3 readouts by 2026.
Market Sentiment Shift: Retail sentiment has shifted, with TERN moving to a bullish outlook while SLS has adopted a bearish stance, reflecting differing investor confidence in their respective stocks.
Financial Opportunities and Strategies: Merck anticipates a $70 billion commercial opportunity beyond Keytruda, as it prepares for the expected loss of exclusivity in 2028, while also expanding its newer Keytruda QLEX formulation.
Stock Performance and Analyst Ratings: SLS stocks have shown a significant upside potential, with a consensus rating of 'Strong Buy', while TERN's stock has also gained traction, reflecting a broader positive sentiment in the oncology sector.
See More
Merck Nears $6 Billion Acquisition of Terns Pharmaceuticals
- Acquisition Progress: Merck & Co. is nearing an approximately $6 billion all-cash deal to acquire US biotech firm Terns Pharmaceuticals, aiming to bolster its drug pipeline ahead of the patent expiration of cancer treatment Keytruda.
- Positive Market Reaction: Following the news, Terns Pharmaceuticals' shares rose about 10% in after-hours trading, reflecting optimistic market sentiment and indicating investor confidence in its chronic myeloid leukemia treatment potential.
- Strategic Positioning: Merck CEO Rob Davis is spearheading a diversification strategy to enhance the company's competitiveness ahead of Keytruda's patent expiration in 2028, demonstrating a strong commitment to future drug development.
- Market Capitalization: As of Tuesday's close, Terns had a market capitalization of $5.4 billion, and Merck's acquisition intentions not only aim to enhance its drug portfolio but also potentially lay the groundwork for future growth.
See More
MERCK AND TERNS IN FINAL STAGES OF DISCUSSIONS, DEAL POSSIBLE SOON - FT
- Negotiations Update: Talks between Merck and Terna are currently taking place at an advanced stage.
- Potential Agreement: A deal between the two companies could be reached in the coming days.
See More
MERCK'S CASH OFFER IS PROJECTED TO VALUATE TERNS AT ABOUT $6 BILLION - FT
- Merck's All-Cash Deal: Merck is expected to finalize an all-cash deal valued at approximately $6 billion.
- Valuation Expectations: The deal is anticipated to significantly enhance Merck's market valuation.
See More
Organon 2025 Financial Results and Outlook Analysis
- Revenue Decline: Organon reported approximately $6.216 billion in revenue for 2025, a 3% year-over-year decline, reflecting challenges in its women's health and biosimilars segments, particularly a 9% drop in the U.S. market due to policy-related access restrictions.
- Leadership Change: CEO Kevin Ali resigned following an internal investigation, with Joseph Morrissey appointed as interim CEO; while the financial impact of this change is described as small, it has affected investor sentiment and led to stock price volatility.
- Cash Flow and Debt Management: In 2025, Organon generated about $700 million in net cash flow, and despite facing total debt of $8.64 billion, management is focused on debt reduction, aiming to significantly lower net debt levels before the 2028 refinancing deadline.
- Portfolio Risk: Although the biosimilars segment grew by 4% in 2025, the decline in sales of mature products like Nexplanon by 4% and market access restrictions indicate that Organon's product portfolio faces ongoing market pressures, limiting future growth potential.
See More
